Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes

Diabetes Care

Volumn 36, Issue SUPPL.2, 2013, Pages

  DeFronzo, Ralph A ^a   Eldor, Roy ^a   Bdul Ghani, Muhammad A ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; HEMOGLOBIN A1C; INSULIN; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE;

ALGORITHM; ARTICLE; BLOOD GLUCOSE MONITORING; CELL FUNCTION; EXERCISE; HUMAN; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PATHOPHYSIOLOGY; TREAT TO FAIL ALGORITHM;

ALGORITHMS; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; LIVER; METFORMIN; MUSCLES;

EID: 84886689057     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dcS13-2011     Document Type: Article

References (192)

1. Nathan DM, Buse JB, Davidson MB, et al.; American Diabetes Association; European Association for Study of Diabetes. Medical management of hyper-glycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193-203
2. Schernthaner G, Barnett AH, Betteridge DJ, et al. Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis. Diabetologia 2010;53:1258-1269
3. Defronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009;58:773-795
4. Pozzilli P, Leslie RD, Chan J, et al. The A1C and ABCD of glycaemia management in type 2 diabetes: a physician's personalized approach. Diabetes Metab Res Rev 2010;26:239-244
5. Inzucchi SE, Bergenstal RM, Buse JB, et al.; American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364-1379
6. Abdul-Ghani MA, Matsuda M, Sabbah M, Jenkinson C, Richardson DK, De-Fronzo RA. The relative contribution of insulin resistance and beta cell failure to the transition from normal to impaired glucose tolerance varies in different ethnic groups. Diab Metab Syndr 2007;1: 105-112
7. DeFronzo RA. Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 1988;37:667-687
8. DeFronzo RA. Pathogenesis of type 2 diabetes: metabolic and molecular implications for identifying diabetes genes. Diabetes Res 1997;5:177-269
9. Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, DeFronzo RA; San Antonio metabolism study. Beta-cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study. Diabetologia 2004;47:31-39
10. Ferrannini E, Gastaldelli A, Miyazaki Y, Matsuda M, Mari A, DeFronzo RA. beta-Cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis. J Clin Endocrinol Metab 2005;90:493-500
11. Abdul-Ghani MA, Tripathy D, DeFronzo RA. Contributions of beta-cell dysfunction and insulin resistance to the patho-genesis of impaired glucose tolerance and impaired fasting glucose. Diabetes Care 2006;29:1130-1139
12. Abdul-Ghani MA, Jenkinson CP, Richardson DK, Tripathy D, DeFronzo RA. Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance: results from the Veterans Administration Genetic Epidemiology Study. Diabetes 2006;55: 1430-1435
13. Eriksson J, Franssila-Kallunki A, Ekstrand A, et al. Early metabolic defects in persons at increased risk for non-insulin-dependent diabetes mellitus. N Engl J Med 1989;321:337-343
14. Groop L, Lyssenko V. Genes and type 2 diabetes mellitus. Curr Diab Rep 2008;8: 192-197
15. Ahlqvist E, Ahluwalia TS, Groop L. Genetics of type 2 diabetes. Clin Chem 2011;57:241-254
16. DeFronzo RA, Ferrannini E, Simonson DC. Fasting hyperglycemia in non-insulin-dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake. Metabolism 1989;38: 387-395
17. Groop LC, Bonadonna RC, DelPrato S, et al. Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus. Evidence for multiple sites of insulin resistance. J Clin Invest 1989;84: 205-213
18. Ferrannini E, Simonson DC, Katz LD, et al. The disposal of an oral glucose load in patients with non-insulin-dependent diabetes. Metabolism 1988;37:79-85
19. DeFronzo RA, Gunnarsson R, Björkman O, Olsson M, Wahren J. Effects of insulin on peripheral and splanchnic glucose metabolism in noninsulin-dependent (type II) diabetes mellitus. J Clin Invest 1985;76:149-155
20. Pendergrass M, Bertoldo A, Bonadonna R, et al. Muscle glucose transport and phosphorylation in type 2 diabetic, obese nondiabetic, and genetically predisposed individuals. Am J Physiol En-docrinol Metab 2007;292:E92-E100
21. James WP. The fundamental drivers of the obesity epidemic. Obes Rev 2008;9 (Suppl 1):6-13
22. DeFronzo RA, Soman V, Sherwin RS, Hendler R, Felig P. Insulin binding to monocytes and insulin action in human obesity, starvation, and refeeding. J Clin Invest 1978;62:204-213
23. Diamond MP, Thornton K, Connolly-Diamond M, Sherwin RS, DeFronzo RA. Reciprocal variations in insulin-stimulated glucose uptake and pancreatic insulin secretion in women with normal glucose tolerance. J Soc Gynecol Investig 1995;2:708-715
24. Saad MF, Knowler WC, Pettitt DJ, Nelson RG, Mott DM, Bennett PH. Sequential changes in serum insulin concentration during development of non-insulin-dependent diabetes. Lancet 1989;1:1356-1359
25. Lillioja S, Mott DM, Howard BV, et al. Impaired glucose tolerance as a disorder of insulin action. Longitudinal and cross-sectional studies in Pima Indians. N Engl J Med 1988;318:1217-1225
26. Lillioja S, Mott DM, Spraul M, et al. Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians. N Engl J Med 1993;329:1988-1992
27. Weyer C, Tataranni PA, Bogardus C, Pratley RE. Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes development. Diabetes Care 2001; 24:89-94
28. Levy J, Atkinson AB, Bell PM, McCance DR, Hadden DR. Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: the 10-year follow-up of the Belfast Diet Study. Di-abet Med 1998;15:290-296
29. Bergman RN, Finegood DT, Kahn SE. The evolution of beta-cell dysfunction and insulin resistance in type 2 diabetes. Eur J Clin Invest 2002;32(Suppl. 3):35-45
30. Jallut D, Golay A, Munger R, et al. Impaired glucose tolerance and diabetes in obesity: a 6-year follow-up study of glucose metabolism. Metabolism 1990; 39:1068-1075
31. Felber JP, Golay A, Jéquier E, et al. The metabolic consequences of long-term human obesity. Int J Obes 1988;12:377-389
32. Ahren B, Taborsky GJ. Beta-cell function and insulin secretion. In Ellenberg and Rifkin's Diabetes Mellitus. Porte D, Sherin RS, Baron A, Eds. New York, McGraw Hill, 2003, p. 43-65
33. Bergman RN. Lilly lecture 1989. Toward physiological understanding of glucose tolerance. Minimal-model approach. Diabetes 1989;38:1512-1527
34. Zimmet P, Whitehouse S, Alford F, Chisholm D. The relationship of insulin response to a glucose stimulus over a wide range of glucose tolerance. Dia-betologia 1978;15:23-27
35. Saad MF, Knowler WC, Pettitt DJ, Nelson RG, Mott DM, Bennett PH. The natural history of impaired glucose tolerance in the Pima Indians. N Engl J Med 1988;319:1500-1506
36. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003;52:102-110
37. Rahier J, Guiot Y, Goebbels RM, Sempoux C, Henquin JC. Pancreatic beta-cell mass in European subjects with type 2 diabetes. Diabetes Obes Metab 2008;10(Suppl. 4):32-42
38. Stefan Y, Orci L, Malaisse-Lagae F, Perrelet A, Patel Y, Unger RH. Quantitation of endocrine cell content in the pancreas of nondiabetic and diabetic humans. Diabetes 1982;31:694-700
39. Shulman GI, Rothman DL, Smith D, et al. Mechanism of liver glycogen repletion in vivo by nuclear magnetic resonance spectroscopy. J Clin Invest 1985; 76:1229-1236
40. Bajaj M, Defronzo RA. Metabolic and molecular basis of insulin resistance. J Nucl Cardiol 2003;10:311-323
41. Cusi K, Maezono K, Osman A, et al. Insulin resistance differentially affects the PI 3-kinase-and MAP kinase-mediated signaling in human muscle. J Clin Invest 2000;105:311-320
42. DeFronzo RA. Insulin resistance, lipo-toxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009. Diabetologia 2010; 53:1270-1287
43. Nauck MA, Vardarli I, Deacon CF, Holst JJ, Meier JJ. Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down? Diabetologia 2011;54:10-18
44. Knop FK, Vilsbøll T, Højberg PV, et al. Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state? Diabetes 2007;56:1951-1959
45. Holst JJ. Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005. Diabetologia 2006;49: 253-260
46. Baron AD, Schaeffer L, Shragg P, Kolterman OG. Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type II diabetics. Diabetes 1987;36:274-283
47. Matsuda M, Defronzo RA, Glass L, et al. Glucagon dose-response curve for hepatic glucose production and glucose disposal in type 2 diabetic patients and normal individuals. Metabolism 2002; 51:1111-1119
48. Abdul-Ghani MA, Norton L, Defronzo RA. Role of sodium-glucose cotrans-porter 2 (SGLT 2) inhibitors in the treat-mentof type2 diabetes. Endocr Rev 2011; 32:515-531
49. Mogensen CE. Maximum tubular re-absorption capacity for glucose and renal hemodynamcis during rapid hypertonic glucose infusion in normal and diabetic subjects. Scand J Clin Lab Invest 1971; 28:101-109
50. Matsuda M, Liu Y, Mahankali S, et al. Altered hypothalamic function in response to glucose ingestion in obese humans. Diabetes 1999;48:1801-1806
51. Obici S, Feng Z, Karkanias G, Baskin DG, Rossetti L. Decreasing hypothalamic insulin receptors causes hyperphagia and insulin resistance in rats. Nat Neurosci 2002;5:566-572
52. Obici S, Feng Z, Tan J, Liu L, Karkanias G, Rossetti L. Central melanocortin receptors regulate insulin action. J Clin Invest 2001;108:1079-1085
53. Cusi K, Consoli A, DeFronzo RA. Metabolic effects of metformin on glucose and lactate metabolism in NIDDM. J Clin Endocrinol Metab 1996;81:4059-4067
54. DeFronzo RA, Goodman AM; The Mul-ticenter Metformin Study Group. Efficacy of metformin in patients with non-insulin-dependent diabetes mel-litus. N Engl J Med 1995;333:541-549
55. Cusi K, DeFronzo RA. Metformin: a review of its metabolic effects. Diabetes Res 1998;6:89-131
56. Miyazaki Y, Mahankali A, Matsuda M, et al. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with piogli-tazone. Diabetes Care 2001;24:710-719
57. Miyazaki Y, Mahankali A, Matsuda M, et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endo-crinol Metab 2002;87:2784-2791
58. Bajaj M, Suraamornkul S, Hardies LJ, Pratipanawatr T, DeFronzo RA. Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone-treated type II diabetic patients. Int J Obes Relat Metab Disord 2004;28:783-789
59. Gastaldelli A, Miyazaki Y, Mahankali A, et al. The effect of pioglitazone on the liver: role of adiponectin. Diabetes Care 2006;29:2275-2281
60. Gastaldelli A, Miyazaki Y, Pettiti M, et al. The effect of rosiglitazone on the liver: decreased gluconeogenesis in patients with type 2 diabetes. J Clin Endocrinol Metab 2006;91:806-812
61. Miyazaki Y, DeFronzo RA. Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients. Diabetes Obes Metab 2008;10:1204-1211
62. Bays H, Mandarino L, DeFronzo RA. Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. J Clin Endocrinol Metab 2004;89:463-478
63. Bajaj M, Baig R, Suraamornkul S, et al. Effect of pioglitazone on intramocellular fat metabolism in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2010;95:1916-1923
64. Natali A, Ferrannini E. Effects of met-formin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic review. Di-abetologia 2006;49:434-441
65. Miyazaki Y, He H, Mandarino LJ, DeFronzo RA. Rosiglitazone improves downstream insulin receptor signaling in type 2 diabetic patients. Diabetes 2003;52:1943-1950
66. Musi N, Hirshman MF, Nygren J, et al. Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes 2002;51:2074-2081
67. Einhorn D, Rendell M, Rosenzweig J, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglita-zone 027 Study Group. Clin Ther 2000; 22:1395-1409
68. Fonseca V, Rosenstock J, Patwardhan R, Salzman A. Effect of metformin and ro-siglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA 2000;283:1695-1702
69. Matthews DR, Charbonnel BH, Hanefeld M, Brunetti P, Schernthaner G. Long-term therapy with addition of pioglita-zone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study. Diabetes Metab Res Rev 2005;21:167-174
70. Charbonnel B, Schernthaner G, Brunetti P, et al. Long-term efficacy and tolera-bility of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes. Diabetologia 2005;48:1093-1104
71. Inzucchi SE, Maggs DG, Spollett GR, et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med 1998; 338:867-872
72. Bajaj M, DeFronzo RA. Combination therapy in type 2 diabetes. In International Textbook of Diabetes Mellitus. 3rd ed. DeFronzo RA, Ferrannini E, Keen H, Zimmet P, Eds. Hoboken, NJ, John Wiley & Sons, 2004, p. 915-950
73. Miyazaki Y, Glass L, Triplitt C, et al. Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients. Diabetologia 2001; 44:2210-2219
74. Bajaj M, Suraamornkul S, Pratipanawatr T, et al. Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes. Diabetes 2003;52:1364-1370
75. Belfort R, Harrison SA, Brown K, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohe-patitis. N Engl J Med 2006;355:2297-2307
76. Yki-Järvinen H. Thiazolidinediones. N Engl J Med 2004;351:1106-1118
77. Lim EL, Hollingsworth KG, Aribisala BS, Chen MJ, Mathers JC, Taylor R. Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol. Dia-betologia 2011;54:2506-2514
78. Anderson JW, Konz EC, Frederich RC, Wood CL. Long-term weight-loss maintenance: a meta-analysis of US studies. Am J Clin Nutr 2001;74:579-584
79. Dansinger ML, Tatsioni A, Wong JB, Chung M, Balk EM. Meta-analysis: the effect of dietary counseling for weight loss. Ann Intern Med 2007;147:41-50
80. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999;131:281-303
81. Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, Mari A, DeFronzo RA. Thiazolidinediones improve beta-cell function in type 2 diabetic patients. Am J Physiol Endocrinol Metab 2007;292: E871-E883
82. Kahn SE, Haffner SM, Heise MA, et al.; ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or gly-buride monotherapy. N Engl J Med 2006; 355:2427-2443
83. Kahn SE, Lachin JM, Zinman B, et al.; ADOPT Study Group. Effects of rosigli-tazone, glyburide, and metformin on b-cell function and insulin sensitivity in ADOPT. Diabetes 2011;60:1552-1560
84. Bunck MC, Cornér A, Eliasson B, et al. Effects of exenatide on measures of b-cell function after 3 years in metformin-treated patients with type 2 diabetes. Diabetes Care 2011;34:2041-2047
85. Bunck MC, Diamant M, Cornér A, et al. One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care 2009;32: 762-768
86. Chang AM, Jakobsen G, Sturis J, et al. The GLP-1 derivative NN2211 restores beta-cell sensitivity to glucose in type 2 diabetic patients after a single dose. Diabetes 2003;52:1786-1791
87. Mazzone T, Meyer PM, Feinstein SB, et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 2006;296:2572-2581
88. Nissen SE, Nicholls SJ, Wolski K, et al.; PERISCOPE Investigators. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 2008;299:1561-1573
89. Hanefeld M, Pfutzner A, Forst T, Lubben G. Glycemic control and treatment failure with pioglitazone versus gliben-clamide in type 2 diabetes mellitus: a 42-month, open-label, observational, primary care study. Curr Med Res Opin 2006;22:1211-1215
90. Tan MH, Baksi A, Krahulec B, et al.; GLAL Study Group. Comparison of pio-glitazone and gliclazide in sustaining glycemic control over 2 years in patients with type 2 diabetes. Diabetes Care 2005; 28:544-550
91. Rosenstock J, Goldstein BJ, Vinik AI, et al.; RESULT Study Group. Effect of early addition of rosiglitazone to sul-phonylurea therapy in older type 2 diabetes patients (.60 years): the Rosi-glitazone Early vs. SULphonylurea Ti-tration (RESULT) study. Diabetes Obes Metab 2006;8:49-57
92. Home PD, Jones NP, Pocock SJ, et al.; RECORD Study Group. Rosiglitazone RECORD study: glucose control outcomes at 18 months. Diabet Med 2007; 24:626-634
93. Klonoff DC, Buse JB, Nielsen LL, et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 2008;24:275-286
94. Bergenstal RM, Wysham C, Macconell L, et al.; DURATION-2 Study Group. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet 2010;376:431-439
95. Matthews DR, Dejager S, Ahren B, et al. Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with gli-mepiride, with no weight gain: results from a 2-year study. Diabetes Obes Metab 2010;12:780-789
96. Gallwitz B, Rosenstock J, Rauch T, et al. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. Lancet 2012;380:475-483
97. Astrup A, Carraro R, Finer N, et al.; NN8022-1807 Investigators. Safety, tol-erability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond) 2012;36:843-854
98. Cervera A, Wajcberg E, Sriwijitkamol A, et al. Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes. Am J Physiol Endocrinol Metab 2008;294:E846-E852
99. Cersosimo E, Gastaldelli A, Cervera A, et al. Effect of exenatide on splanchnic and peripheral glucose metabolism in type 2 diabetic subjects. J Clin Endo-crinol Metab 2011;96:1763-1770
100. Chilton R, Wyatt J, Nandish S, Oliveros R, Lujan M. Cardiovascular comorbid-ities of type 2 diabetes mellitus: defining the potential of glucagonlike peptide-1-based therapies. Am J Med 2011;124 (Suppl.):S35-S53
101. Jenkins AJ, Krishnamurthy B, Best JD, et al. Evaluation of an algorithm to guide patients with type 1 diabetes treated with continuous subcutaneous insulin infusion on how to respond to real-time continuous glucose levels: a randomized controlled trial. Diabetes Care 2010;33: 1242-1248
102. Marso SP, Lindsey JB, Stolker JM, et al. Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of phase 2: 3 liraglutide clinical development studies. Diab Vasc Dis Res 2011; 8:237-240
103. Herman GA, Bergman A, Stevens C, et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on in-cretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab 2006;91:4612-4619
104. DeFronzo RA, Okerson T, Viswanathan P, Guan X, Holcombe JH, MacConell L. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glu-cagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. Curr Med Res Opin 2008;24: 2943-2952
105. Pratley RE, Nauck M, Bailey T, et al.; 1860-LIRA-DPP-4 Study Group. Lir-aglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with met-formin: a 26-week, randomised, parallel-group, open-label trial. Lancet 2010; 375:1447-1456
106. Mulherin AJ, Oh AH, Kim H, Grieco A, Lauffer LM, Brubaker PL. Mechanisms underlying metformin-induced secretion of glucagon-like peptide-1 from the intestinal L cell. Endocrinology 2011; 152:4610-4619
107. Mannucci E, Ognibene A, Cremasco F, et al. Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects. Diabetes Care 2001;24:489-494
108. Migoya EM, Bergeron R, Miller JL, et al. Dipeptidyl peptidase-4 inhibitors administered in combination with metfor-min result in an additive increase in the plasma concentration of active GLP-1. Clin Pharmacol Ther 2010;88:801-808
109. Ahrén B, Landin-Olsson M, Jansson PA, Svensson M, Holmes D, Schweizer A. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 2004; 89:2078-2084
110. DeFronzo RA, Davidson JA, Del Prato S. The role of the kidneys in glucose ho-meostasis: a new path towards normalizing glycaemia. Diabetes Obes Metab 2012;14:5-14
111. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009;15:540-559
112. Zinman B, Harris SB, Neuman J, et al. Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study. Lancet 2010;376:103-111
113. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853
114. Turner RC, Cull CA, Frighi V, Holman RR; UK Prospective Diabetes Study (UKPDS) Group. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 1999;281: 2005-2012
115. Holman RR, Haffner SM, McMurray JJ, et al.; NAVIGATOR Study Group. Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med 2010;362:1463-1476
116. Gerich J, Raskin P, Jean-Louis L, Purkayastha D, Baron MA. PRESERVE-beta: two-year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin. Diabetes Care 2005;28:2093-2099
117. Takahashi A, Nagashima K, Hamasaki A, et al. Sulfonylurea and glinide reduce insulin content, functional expression of K(ATP) channels, and accelerate ap-optotic beta-cell death in the chronic phase. Diabetes Res Clin Pract 2007;77: 343-350
118. Hambrock A, de Oliveira Franz CB, Hiller S, Osswald H. Glibenclamide-induced apoptosis is specifically enhanced by expression of the sulfonylurea receptor isoform SUR1 but not by expression of SUR2B or the mutant SUR1 (M1289T). J Pharmacol Exp Ther 2006; 316:1031-1037
119. Maedler K, Carr RD, Bosco D, Zuellig RA, Berney T, Donath MY. Sulfonylurea induced beta-cell apoptosis in cultured human islets. J Clin Endocrinol Metab 2005;90:501-506
120. Kim JY, Lim DM, Park HS, et al. Ex-endin-4 protects against sulfonylurea-induced b-cell apoptosis. J Pharmacol Sci 2012;118:65-74
121. Johnson JA, Majumdar SR, Simpson SH, Toth EL. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care 2002;25:2244-2248
122. Evans JM, Ogston SA, Emslie-Smith A, Morris AD. Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Dia-betologia 2006;49:930-936
123. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352: 854-865
124. U.K. Prospective Diabetes Study Group. UKPDS 28: a randomized trial of efficacy of early addition of metformin in sulfo-nylurea-treated type 2 diabetes. Diabetes Care 1998;21:87-92
125. Wright A, Burden AC, Paisey RB, Cull CA, Holman RR; U.K. Prospective Diabetes Study Group. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care 2002; 25:330-336
126. Matthews DR, Cull CA, Stratton IM, Holman RR, Turner RC; UK Prospective Diabetes Study (UKPDS) Group. UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. Diabet Med 1998;15:297-303
127. U.K. Prospective Diabetes Study Group. U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995;44:1249-1258
128. Lupi R, Del Guerra S, Tellini C, et al. The biguanide compound metformin prevents desensitization of human pancreatic islets induced by high glucose. Eur J Pharmacol 1999;364:205-209
129. Lupi R, Del Guerra S, Fierabracci V, et al. Lipotoxicity in human pancreatic islets and the protective effect of metformin. Diabetes 2002;51(Suppl. 1):S134-S137
130. Brown JB, Conner C, Nichols GA. Secondary failure of metformin monotherapy in clinical practice. Diabetes Care 2010;33:501-506
131. Alvarsson M, Berntorp K, Fernqvist-Forbes E, et al. Effects of insulin versus sulphonylurea on beta-cell secretion in recently diagnosed type 2 diabetes patients: a 6-year follow-up study. Rev Diabet Stud 2010;7:225-232
132. Alvarsson M, Sundkvist G, Lager I, et al. Effects of insulin vs. glibenclamide in recently diagnosed patients with type 2 diabetes: a 4-year follow-up. Diabetes Obes Metab 2008;10:421-429
133. Gallwitz B, Guzman J, Dotta F, et al. Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial. Lancet 2012;379:2270-2278
134. Nieszner E, Posa I, Kocsis E, Pogatsa G, Préda I, Koltai MZ. Influence of diabetic state and that of different sulfonylureas on the size of myocardial infarction with and without ischemic preconditioning in rabbits. Exp Clin Endocrinol Diabetes 2002;110:212-218
135. Panicker GK, Karnad DR, Salvi V, Kothari S. Cardiovascular risk of oral antidiabetic drugs: current evidence and regulatory requirements for new drugs. J Assoc Physicians India 2012;60:56-61
136. Garratt KN, Brady PA, Hassinger NL, Grill DE, Terzic A, Holmes DR Jr. Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction. J Am Coll Cardiol 1999;33: 119-124
137. Simpson SH, Majumdar SR, Tsuyuki RT, Eurich DT, Johnson JA. Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study. CMAJ 2006;174:169-174
138. Schramm TK, Gislason GH, Vaag A, etal. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myo-cardial infarction: a nationwide study. Eur Heart J 2011;32:1900-1908
139. Johnsen SP, Monster TB, Olsen ML, et al. Risk and short-term prognosis of myo-cardial infarction among users of anti-diabetic drugs. Am J Ther 2006;13:134-140
140. Selvin E, Bolen S, Yeh HC, et al. Cardiovascular outcomes in trials of oral diabetes medications: a systematic review. Arch Intern Med 2008;168:2070-2080
141. Rao AD, Kuhadiya N, Reynolds K, Fonseca VA. Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality?: a meta-analysis of observational studies. Diabetes Care 2008;31:1672-1678
142. Roumie CL, Hung AM, Greevy RA, et al. Comparative effectiveness of sulfonyl-urea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study. Ann Intern Med 2012;157:601-610
143. Sillars B, Davis WA, Hirsch IB, Davis TM. Sulphonylurea-metformin combination therapy, cardiovascular disease and all-cause mortality: the Fremantle Diabetes Study. Diabetes Obes Metab 2010;12: 757-765
144. Pantalone KM, Kattan MW, Yu C, et al. The risk of overall mortality in patients with type 2 diabetes receiving glipizide, glyburide, or glimepiride monotherapy: a retrospective analysis. Diabetes Care 2010;33:1224-1229
145. Khalangot M, Tronko M, Kravchenko V, Kovtun V. Glibenclamide-related excess in total and cardiovascular mortality risks: data from large Ukrainian observational cohort study. Diabetes Res Clin Pract 2009;86:247-253
146. Monami M, Balzi D, Lamanna C, et al. Are sulphonylureas all the same? A cohort study on cardiovascular and cancer-related mortality. Diabetes Metab Res Rev 2007;23:479-484
147. Nissen SE, Wolski K. Effect of rosigli-tazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-2471
148. Xiang AH, Peters RK, Kjos SL, et al. Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes. Diabetes 2006;55:517-522
149. Gerstein HC, Yusuf S, Bosch J, et al.; DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006;368:1096-1105
150. Knowler WC, Hamman RF, Edelstein SL, et al.; Diabetes Prevention Program Research Group. Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes 2005;54:1150-1156
151. Buchanan TA, Xiang AH, Peters RK, et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes 2002;51:2796-2803
152. DeFronzo RA, Tripathy D, Schwenke DC, et al.; ACT NOW Study. Pioglita-zone for diabetes prevention in impaired glucose tolerance. N Engl J Med 2011; 364:1104-1115
153. Lupi R, Del Guerra S, Marselli L, et al. Rosiglitazone prevents the impairment of human islet function induced by fatty acids: evidence for a role of PPAR-gamma2 in the modulation of insulin secretion. Am J Physiol Endocrinol Metab 2004;286:E560-E567
154. Finegood DT, McArthur MD, Kojwang D, et al. Beta-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death. Diabetes 2001;50:1021-1029
155. Kim HI, Cha JY, Kim SY, et al. Peroxi-somal proliferator-activated receptor-gamma upregulates glucokinase gene expression in beta-cells. Diabetes 2002; 51:676-685
156. Santini E, Fallahi P, Ferrari SM, Masoni A, Antonelli A, Ferrannini E. Effect of PPAR-gamma activation and inhibition on glucose-stimulated insulin release in INS-1e cells. Diabetes 2004;53(Suppl. 3):S79-S83
157. Masuda K, Okamoto Y, Tsuura Y, et al. Effects of Troglitazone (CS-045) on insulin secretion in isolated rat pancreatic islets and HIT cells: an insulinotropic mechanism distinct from glibenclamide. Diabetologia 1995;38:24-30
158. Betteridge DJ, DeFronzo RA, Chilton RJ. PROactive: time for a critical appraisal. Eur Heart J 2008;29:969-983
159. Patrono C, Bachmann F, Baigent C, et al.; European Society of Cardiology. Expert consensus document on the use of anti-platelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology. Eur Heart J 2004;25:166-181
160. Bajaj M, Suraamornkul S, Hardies LJ, Glass L, Musi N, DeFronzo RA. Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mel-litus. Diabetologia 2007;50:1723-1731
161. Betteridge DJ. Effects of pioglitazone on lipid and lipoprotein metabolism. Diabetes Obes Metab 2007;9:640-647
162. Dormandy JA, Charbonnel B, Eckland DJ, et al.; PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pio-glitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366:1279-1289
163. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007;298:1180-1188
164. Miyazaki M, De Filippis E, Bajaj M, et al. Predictors of improved glycaemic control with rosiglitazone therapy in type 2 diabetic patients: a practical approach for the primary care physician. Br J Diabetes Vasc Dis 2005;5:28-35
165. Singh S, Loke YK, Furberg CD. Thia-zolidinediones and heart failure: a teleo-analysis. Diabetes Care 2007;30: 2148-2153
166. Bodmer M, Meier C, Kraenzlin ME, Meier CR. Risk of fractures with glita-zones: a critical review of the evidence to date. Drug Saf 2009;32:539-547
167. Lewis JD, Ferrara A, Peng T, et al. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care 2011;34:916-922
168. Cohort study of pioglitazone and bladder cancer in patients with type II diabetes [article online], 2013. Available from http://clinicaltrials.gov/ct2/ show/results/NCT01637935?sect=X6015#outcome1. Accessed 4 February 2013
169. Eldor R, DeFronzo RA, Abdul-Ghani M. In vivo actions of peroxisome proliferator-activated receptors: glyce-mic control, insulin sensitivity, and insulin secretion. Diabetes Care 2013;36 (Suppl. 2):S162-S174
170. Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride monotherapy improves glycemic control in the treat ment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care 2000; 23:1605-1611
171. Miyazaki Y, Matsuda M, DeFronzo RA. Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes. Diabetes Care 2002; 25:517-523
172. DeFronzo RA, Burant CF, Fleck P, Wilson C, Mekki Q, Pratley RE. Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes. J Clin Endocrinol Metab 2012;97:1615-1622
173. Yokoyama J, Sutoh N, Higuma T, et al. Efficacy and safety of low-dose pioglita-zone after primary coronary angioplasty with the use of bare metal stent in patients with acute myocardial infarction and with type 2 diabetes mellitus or impaired glucose tolerance. Heart Vessels 2007;22:146-151
174. Aso Y, Hara K, Ozeki N, et al. Low-dose pioglitazone increases serum high molecular weight adiponectin and improves glycemic control in Japanese patients with poorly controlled type 2 diabetes. Diabetes Res Clin Pract 2009;85:147-152
175. Perez A, Zhao Z, Jacks R, Spanheimer R. Efficacy and safety of pioglitazone/metformin fixed-dose combination therapy compared with pioglitazone and metformin monotherapy in treating patients with T2DM. Curr Med Res Opin 2009;25:2915-2923
176. Rosenstock J, Rood J, Cobitz A, Biswas N, Chou H, Garber A. Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes. Diabetes Obes Metab 2006;8:650-660
177. DeFronzo RA, Triplitt C, Qu Y, Lewis MS, Maggs D, Glass LC. Effects of ex-enatide plus rosiglitazone on beta-cell function and insulin sensitivity in subjects with type 2 diabetes on metformin. Diabetes Care 2010;33:951-957
178. Gutzwiller JP, Tschopp S, Bock A, et al. Glucagon-like peptide 1 induces natri-uresis in healthy subjects and in insulin-resistant obese men. J Clin Endocrinol Metab 2004;89:3055-3061
179. Harrison LB, Adams-Huet B, Raskin P, Lingvay I. b-cell function preservation after 3.5 years of intensive diabetes therapy. Diabetes Care 2012;35:1406-1412
180. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev 2007;87:1409-1439
181. Yusta B, Baggio LL, Estall JL, et al. GLP-1 receptor activation improves beta cell function and survival following induction of endoplasmic reticulum stress. Cell Metab 2006;4:391-406
182. Sathyanarayana P, Jogi M, Muthupillai R, Krishnamurthy R, Samson SL, Bajaj M. Effects of combined exenatide and pio-glitazone therapy on hepatic fat content in type 2 diabetes. Obesity (Silver Spring) 2011;19:2310-2315
183. Zinman B, Hoogwerf BJ, Duran Garcia S, et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2007;146:477-485
184. Liutkus J, Rosas Guzman J, Norwood P, et al. A placebo-controlled trial of exenatide twice-daily added to thiazolidi-nediones alone or in combination with metformin. Diabetes Obes Metab 2010; 12:1058-1065
185. Zinman B, Gerich J, Buse J, et al.; LEAD-4 Study Investigators. Efficacy and safety of the human GLP-1 analog liraglutide in combination with metformin and TZD in patients with type 2 diabetes mellitus (LEAD-4 Met+TZD). Diabetes Care 2009; 32:1224-1230
186. Abdul-Ghani MA, Puckett C, Adams J, et al. Initial triple combination therapy is superior to stepwise add-on conventional therapy in newly diagnosed T2DM (Abstract). Diabetes 2013;62(Suppl. 1): A97
187. Deacon CF. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes Obes Metab 2011;13:7-18
188. Raz I, Hanefeld M, Xu L, Caria C, Williams-Herman D, Khatami H; Sita-gliptin Study 023 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 2006;49:2564-2571
189. Yasuda N, Inoue T, Nagakura T, et al. Enhanced secretion of glucagon-like peptide 1 by biguanide compounds. Bi-ochem Biophys Res Commun 2002;298: 779-784
190. Mathieu C, Degrande E. Vildagliptin: a new oral treatment for type 2 diabetes mellitus. Vasc Health Risk Manag 2008; 4:1349-1360
191. Karyekar C, Donovan M, Allen E, Fleming D, Ravichandran S, Chen R. Efficacy and safety of saxagliptin combination therapy in US patients with type 2 diabetes. Postgrad Med 2011;123:63-70
192. Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE; Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 2007;30:1979-1987